A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
11/1999
11/23/1999	US5990329 Retinoids
11/23/1999	US5990299 Control of CD44 gene expression for therapeutic use
11/23/1999	US5990296 Improving binding affinity of single chain lewis-y antibodies by replacing amino acid at position 95 with serine; immunotoxins for anticarcinogenic/antitumor agents
11/23/1999	US5990282 Receptor protein for human B cell stimulatory factor-2
11/23/1999	US5990280 Factor which is heat resistant but sensitive to acidic and alkaline conditions, does not bind heparin, induced by wild type p53 expression, is not thrombospondin, molecular weight of about 100 kilodaltons; diagnosis, anticarcinogenic agents
11/23/1999	US5990149 Photodynamic therapy; using triacid form of the monohydrobenzoporphyrin class; antitumor, carcinogenic, arthritic agents; atherosclerosis; restenosis; blood infections; skin disorders; vision defects
11/23/1999	US5990148 Side effect reductions; antiarthritic agents; nonsteroidal antiinflammatory agents
11/23/1999	US5990145 Antiinflammatory,-carcinogenic,-tumor,-metastasis agents; cardiovascular disorders, e.g., arteriosclerosis, restenosis; retinopaathies and nephropathies; osteoporosis
11/23/1999	US5990135 For treating a retroviral infection such as hiv infection; for example 5s-n-((2-pyridinyl)methoxycarbonyl)valinylamino-2-((n-3 -pyridinyl)methoxycarbonyl)amino-4s-hydroxy-1,6-diphenyl-2-azahexane and other compounds of given formula
11/23/1999	US5990120 Given structure, where a five-membered aza-heterocycle is fused to ring (a) of camptothecin at positions 9 and 10; compounds possess high antitumor activity by inhibition of topoisomerase; methods for their synthesis
11/23/1999	US5990116 Trisubstituted phenyl derivatives
11/23/1999	US5990109 Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors
11/23/1999	US5990090 A double-stranded dna nf-kappab inhibitor of given nucleotide sequence is effective for the treatment of immune and inflammatory diseases, cancer, and viral infections
11/23/1999	US5990088 Method for treating kaposi's sarcoma with antisense oligonucleotides
11/23/1999	US5989908 Nucleic acid encoding ribozyme used for suppression of c-fos oncogene expression in mammalian cells exhibiting multidrug resistant phenotype; increase cell sensitivity to anticarcinogenic/antitumor agents
11/23/1999	US5989856 Pharmaceutical composition having an endoproteolytic activity; a process for endoproteolytically processing (precursor) proteins and for the (micro)biological production of proteins
11/23/1999	US5989850 Methods of testing cancer cells and anticancer drugs
11/23/1999	US5989838 Immunological methods of detecting MN proteins and MN polypeptides
11/23/1999	US5989837 Immortalized human keratinocyte cell line
11/23/1999	US5989822 Diagnosis and treatment of cancer, neurodegenerative and autoimmune diseases; gene expression
11/23/1999	US5989804 E6 binding proteins
11/23/1999	US5989557 Process for extracting polyphenol fractions of tea and compositions produced therewith
11/23/1999	CA1340825C Hyaluronic acid fraction for use as a drug delivery system for medicaments
11/18/1999	WO1999058678A2 Antibodies to dendritic cells and human dendritic cell populations and uses thereof
11/18/1999	WO1999058645A1 New apoptotic bodies, monocyte derived cells containing the same, a process for their preparation and their uses as vaccines
11/18/1999	WO1999058642A2 Secreted proteins and polynucleotides encoding them
11/18/1999	WO1999058570A2 Antibodies to the ed-b domain of fibronectin, conjugates containing them and use therefor for diagnosis and therapy of tumors and diseases associated with angiogenesis
11/18/1999	WO1999058569A1 PLASMIN INHIBITORS FROM THE AUSTRALIAN BROWN SNAKE $i(PSEUDONAJA TEXTILIS TEXTILIS)
11/18/1999	WO1999058565A1 Cystatin-related protein
11/18/1999	WO1999058558A2 Cell signaling proteins
11/18/1999	WO1999058555A2 Water-soluble pro-drugs of 2,6-diisopropylphenol analogues
11/18/1999	WO1999058552A2 Peptides that ellicit t, cellular immunity
11/18/1999	WO1999058546A1 Tumor associated antigen encoded by the reverse strand of a new ubiquitously expressed gene
11/18/1999	WO1999058544A1 Hybrid anthracyclines from genetically engineered streptomyces galilaeus strains
11/18/1999	WO1999058534A2 Epothilone derivatives, a method for the production thereof, and their use
11/18/1999	WO1999058531A1 Novel substituted aryl hydroxamic acids as metalloproteinase inhibitors
11/18/1999	WO1999058528A1 Substituted aryl hydroxamic acids as metalloproteinase inhibitors
11/18/1999	WO1999058523A1 1,5-DIARYL SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS
11/18/1999	WO1999058505A2 Combinations of protein farnesyltransferase and hmg coa reductase inhibitors and their use to treat cancer
11/18/1999	WO1999058502A1 Heterocyclic inhibitors of p38
11/18/1999	WO1999058496A1 Novel substituted cyclic compounds, preparation method and pharmaceutical compositions containing them
11/18/1999	WO1999058495A1 Novel substituted cyclic compounds, preparation method and pharmaceutical compositions containing them
11/18/1999	WO1999058162A2 Pharmaceuticals for the imaging of angiogenic disorders
11/18/1999	WO1999058156A1 Cancer prevention by selective delivery methods
11/18/1999	WO1999058154A1 Protection from ionizing irradiation or chemotherapeutic drug damage by in vivo gene therapy
11/18/1999	WO1999058143A1 Utilization of interferon alpha 5 in the treatment of viral hepatopathies
11/18/1999	WO1999058142A1 Use of anti-prolactin agents to treat proliferative conditions
11/18/1999	WO1999058139A2 Methods for detecting and inhibiting angiogenesis
11/18/1999	WO1999058128A1 Inhibition of protein kinases with piridinylimidazoles
11/18/1999	WO1999058125A1 Metabolites of ecteinascidin 743
11/18/1999	WO1999058096A2 Analogs of 2-phthalimidinoglutaric acid and their use as inhibitors of angiogenesis
11/18/1999	WO1999057981A1 Compositions and methods for active vaccination
11/18/1999	WO1999052562A3 Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor
11/18/1999	WO1999050269A3 Porphyrins and their use as photosensitizer
11/18/1999	WO1999047690A3 Multigene vectors
11/18/1999	WO1999047673A3 Isolated mammalian membrane protein genes and related reagents
11/18/1999	WO1999046284A9 Molecules that home to various selected organs or tissues
11/18/1999	WO1999046283A9 Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
11/18/1999	WO1999046281A9 Novel polypeptides and nucleic acids encoding the same
11/18/1999	WO1999042584A9 Apoptosis inducing molecule ii and methods of use
11/18/1999	WO1999036094A3 Composition and method for treating metastatic tumors or cancer induced by cells expressing sv40 tumor antigen
11/18/1999	WO1999027098A3 A-33 related antigens and their pharmacological uses
11/18/1999	DE19821925A1 Bacteriophage expression system for production of composition for induction of tumor specific responses
11/18/1999	DE19821483A1 New imidazolidine derivatives useful as leukocyte adhesion and migration inhibitors and/or VLA-4 receptor antagonists for treating E.G. inflammatory and allergic disorders
11/18/1999	CA2331878A1 1,5-diaryl substituted pyrazoles as p38 kinase inhibitors
11/18/1999	CA2331569A1 Protection from ionizing irradiation or chemotherapeutic drug damage by in vivo gene therapy
11/18/1999	CA2331371A1 Water-soluble pro-drugs of propofol
11/18/1999	CA2331295A1 Combinations of protein farnesyltransferase and hmg coa reductase inhibitors and their use to treat cancer
11/18/1999	CA2331115A1 New apoptotic bodies, monocyte derived cells containing the same, a process for their preparation and their uses as vaccines
11/18/1999	CA2330812A1 Epothilone derivatives, a method for the production thereof, and their use
11/18/1999	CA2330212A1 Compositions and methods for active vaccination
11/18/1999	CA2330108A1 Novel substituted aryl hydroxamic acids as metalloproteinase inhibitors
11/18/1999	CA2330095A1 Substituted aryl hydroxamic acids as metalloproteinase inhibitors
11/18/1999	CA2328520A1 Use of anti-prolactin agents to treat proliferative conditions
11/18/1999	CA2328414A1 Methods for detecting and inhibiting angiogenesis
11/18/1999	CA2328405A1 Tumor associated antigen encoded by the reverse strand of a new ubiquitously expressed gene
11/18/1999	CA2328062A1 Secreted proteins and polynucleotides encoding them
11/18/1999	CA2327549A1 Peptides that induce t cell responses
11/18/1999	CA2327386A1 Inhibition of protein kinases with piridinylimidazoles
11/18/1999	CA2327351A1 Cell signaling proteins
11/18/1999	CA2324555A1 Pharmaceuticals for the imaging of angiogenic disorders
11/17/1999	EP0957099A2 Heterocyclic carboxamides
11/17/1999	EP0957091A1 Inhibitors of tumor necrosis factor alpha
11/17/1999	EP0956865A1 MEDICINES COMPRISING Rho KINASE INHIBITOR
11/17/1999	EP0956506A1 Treatment and diagnosis of cancer
11/17/1999	EP0956351A1 A tumor necrosis factor related ligand
11/17/1999	EP0956350A1 Human chloride channel protein (hccp)
11/17/1999	EP0956303A2 Non-naturally occurring lipoprotein particle
11/17/1999	EP0956299A1 Peptide antagonists of dp transcription factors
11/17/1999	EP0956294A1 Thrombin inhibitors
11/17/1999	EP0956053A1 Method for treating neoplasia using humanized antibodies which bind to antigen a33
11/17/1999	EP0956046A2 Cellular vaccines and immunotherapeutics and methods for their preparation
11/17/1999	EP0956040A1 Stimulation of host defense mechanisms against viral challenges
11/17/1999	EP0956033A1 Total synthesis of the amino hip analogue of didemnin a
11/17/1999	EP0956032A1 Proteins and compositions for modulating mitosis
11/17/1999	EP0956028A1 Submucosal tissue inhibition of neoplastic cell growth
11/17/1999	EP0956027A1 Semi-synthetic sulphaminoheparosansulphates having high anti-metastatic activity and reduced haemorrhagic risk
11/17/1999	EP0956021A1 L-$g(b)-DIOXOLANE URIDINE ANALOGS AND METHODS FOR TREATING AND PREVENTING VIRUS INFECTIONS
11/17/1999	EP0956017A1 Benzimidazole-2-carbamates for the treatment of viral infections and cancer
11/17/1999	EP0956016A1 Pharmaceutical compounds comprising polyamines substituted with electron-affinic groups

1 ... 1939 1940 1941 1942 1943 1944 1945 1946 1947 1948 1949 1950 1951 1952 1953 1954 1955 1956 1957 1958 1959 ... 2211